The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?: Targeting the cellular micro-ribonucleic acids?

Elias A Said

The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids? Targeting the cellular micro-ribonucleic acids?

Elias A Said

Microbiology & Immunology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.

Original language	English
Pages (from-to)	312-317
Number of pages	6
Journal	Sultan Qaboos University Medical Journal
Volume	10
Issue number	3
Publication status	Published - Dec 2010

Keywords

Hepatitis C virus
Infection
Interferon
Liver
MicroRNAs
Therapy

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{4c3a35d4c7384312a97189ca57bfef4b,

title = "The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?: Targeting the cellular micro-ribonucleic acids?",

abstract = "Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.",

keywords = "Hepatitis C virus, Infection, Interferon, Liver, MicroRNAs, Therapy",

author = "Said, {Elias A}",

year = "2010",

month = dec,

language = "English",

volume = "10",

pages = "312--317",

journal = "Sultan Qaboos University Medical Journal",

issn = "2075-051X",

publisher = "Sultan Qaboos University",

number = "3",

}

TY - JOUR

T1 - The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?

T2 - Targeting the cellular micro-ribonucleic acids?

AU - Said, Elias A

PY - 2010/12

Y1 - 2010/12

N2 - Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.

AB - Infection with the hepatitis C virus (HCV) is a worldwide problem. Patients with chronic HCV infection who are non-responders to standard therapy represent a growing population within the HCV epidemic. Novel, more efficient and tolerable therapies are urgently needed. This review discusses the recent results showing that targeting miR-122, a micro-ribonucleic acid (MicroRNA) that enhances HCV replication, is a new anti-HCV therapy with a high barrier to resistance.

KW - Hepatitis C virus

KW - Infection

KW - Interferon

KW - Liver

KW - MicroRNAs

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84870288172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870288172&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84870288172

SN - 2075-051X

VL - 10

SP - 312

EP - 317

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

IS - 3

ER -